ေသြးက်ေဆး ၃ မ်ိဳးဟာ ကင္ဆာေရာဂါ ျဖစ္ေစႏိုင္သည္ဟု အတည္ျပဳ

ေသြးက်ေဆး ၃ မ်ိဳးဟာ ကင္ဆာေရာဂါ ျဖစ္ေစႏိုင္သည္ဟု အတည္ျပဳ

စင္ကာပူမွာ လူနာေပါင္း ၁ သိန္းေက်ာ္ဟာ အဆိုပါ ေဆးမ်ားကို လက္ရွိ ေသာက္သံုးေနတာပါ။

စင္ကာပူမွာ ေသြးတိုးအတြက္ ေသာက္ေဆး ၃ မ်ိဳးဟာ ကင္ဆာေရာဂါျဖစ္ေစႏိုင္တာမို႔ က်န္းမာေရးဝန္ႀကီးဌာနမွ အဆိုပါေသြးက်ေဆးမ်ား ေသာက္ေနသူ လူနာမ်ားကို  ျပန္ၿပီး ေဆးစစ္ႏိုင္ဖို႔ စီစဥ္ေနပါၿပီ။

အဆိုပါ ေဆး ၃ မ်ိဳးကေတာ့

(၁) Hyperten tablet

(၂) Losagan tablet

(၃) Losartas tablet. တို႔ ျဖစ္ပါတယ္။ ပံုထဲက ဇယားထဲမွာ ေဆးနာမည္၊ စင္ကာပူမွာ ေဆးေရာင္းတဲ့ ကုမၸဏီနဲ႔ ေဆးပမာဏကိုပါ အလြယ္တကူ နားလည္ႏိုင္ရန္ေဖာ္ျပထားပါတယ္။

က်န္းမာေရးဝန္ႀကီးဌာန လက္ေအာက္ခံ ေဆးရံု ေဆးခန္းမ်ားမွ ေသြးတိုးရွိသူ လူနာမ်ားအတြက္ အမ်ားဆံုး အသံုးျပဳေနတဲ့ အဆိုပါ  ေဆး မွာ ပါဝင္တဲ့  losartan postassium ေဆးပစၥည္းဟာ ေသာက္သံုးသူလူနာမ်ားကို ေရရွည္မွာ ကင္ဆာေရာဂါ ခံစားေစႏိုင္တယ္ဆိုတာ စမ္းသပ္ခ်က္မ်ားအရ အတည္ျပဳလိုက္ၿပီမို႔ လက္ရွိ ေသာက္သံုးရန္ ၫႊန္းထာသူ လူနာမ်ားကို ေဆးမ်ားကို ဆက္ၿပီး မေသာက္ရန္ အသိေပးထားပါတယ္။ 

အဆိုပါ losartan postassium ေဆးပစၥည္းကို အိႏိၵယႏိုင္ငံ ေဆးဝါးစက္ရံု တစ္ရံုမွ ထုတ္လုပ္ေနတယ္လို႔ ဆိုပါတယ္။

လက္ရွိ မွတ္တမ္းအရ စင္ကာပူမွာ အဆိုပါ  ကို ေသာက္သံုးေနသူ လူနာေပါင္း ၁၃၇,၀၀၀ ရွိေနပါတယ္။ ဒါေၾကာင့္ အဆိုပါေဆးမ်ား ေသာက္ေနတဲ့ လူနာမ်ားရဲ႕ က်န္းမာေရးအေျခအေနကိုစစ္ေဆးဖို႔ သက္ဆိုင္ရာ ေဆးရံု ေဆးခန္းမ်ားမွ တဆင့္ အေၾကာင္းၾကားပါလိမ့္မယ္။ 

ေဆးဝါးအတြက္ အသံုးျပဳတဲ့ ေဆးပစၥည္းေတြထဲမွာ ပါဝင္တဲ့ nitrosamine inpurity, N-nitro-N-methyl-4-aminobutyric acid (NMBA) ဟာ ႏိုင္ငံတစ္ကာ ခြင့္ျပဳတဲ့ သတ္မွတ္နႈႏ္ူထားတဲ့ ေက်ာ္လြန္ေနတယ္လို႔ ဆိုပါတယ္။ nitrosamines ဓာတ္ ေသာက္သံုးမႈမ်ားလာပါက ကင္ဆာ ေရာဂါျဖစ္ႏိုင္တဲ့ အႏၲရာယ္ရွိတာကိုလည္း စင္ကာပူ HSA မွ သတင္း ဌာနကို ရွင္းျပထားပါတယ္။

ျမန္မာေတြထဲမွာ အဆိုပါ ေဆး ၃ မ်ိဳးကို ေသြးတိုးေရာဂါအတြက္ ေသာက္သံုးေနရင္ ေသာက္ေနရာမွ ခ်က္ျခင္း ရပ္တန္႔တာမ်ိဳး မလုပ္ဘဲ ဆရာဝန္နဲ႔ တိုင္ပင္ကာ အစားထိုးမည့္ ေဆးကို ဆရာရဲ႕ ၫႊန္ၾကားမႈကို ခံယူသင့္ပါတယ္လို႔ သတင္းမွာ ေရးထားပါတယ္။

ဇူလိုင္လ ၁ ရက္ေန႔ မတိုင္ခင္ ေဆးစစ္ေဆးရန္ ရက္ခ်ိန္းယူၿပီးသားသူမ်ားအတြက္ ဆက္ၿပီး ေဆးစစ္ခ်က္ရယူပါလို႔ တိုက္တြန္းထားသလို ေနာက္ပိုင္းရက္မ်ားမွာ ရက္ခ်ိန္းယူထားသူမ်ားကိုေတာ့ ေဆးရံု ေဆးခန္းမ်ားမွ ဆက္သြယ္ၿပီး ရက္ခ်ိန္းအတြက္ စီစဥ္မယ္လို႔ သတင္းမွာ ေဖာ္ျပထားပါတယ္။

အထူး သတိျပဳရန္ - ေသာက္လက္စေဆးကို ခ်က္ျခင္း မရပ္ပါႏွင့္၊ ေဆးအစားထိုးရန္ ဆရာဝန္ရဲ႕ ၫႊန္ၾကားခ်က္ရယူပါ။

သတင္းမူရင္း - CNA

https://www.channelnewsasia.com/news/singapore/hsa-recalls-3-brands-blood-pressure-drugs-losartan-impurity-11389238

HSA recalls 3 brands of high blood pressure drugs over potentially harmful impurity

SINGAPORE: Three brands of high blood pressure medicine containing the ingredient losartan have been recalled because they contain higher than acceptable levels of a potentially harmful impurity, the Health Sciences Authority (HSA) said on Thursday (Mar 28).

The drugs contain the active ingredient losartan potassium, which was manufactured by Indian pharmaceutical company Hetero Labs.

The affected products are the 50mg and 100mg tablets from the brands Losartas, Losagen and Hyperten and distributed by local suppliers Apotheca Marketing, Medicell Pharmaceutical and Goldplus Universal, respectively.

About 137,000 patients in Singapore are using the three recalled brands of losartan medicine, said the Ministry of Health (MOH).

Losartas is prescribed in public healthcare institutions, while Losartas, Losagen and Hyperten are prescribed at private healthcare institutions.

HSA has advised patients not to stop treatment on their own as there is no immediate health risk and sudden stopping of the drugs can pose greater immediate risk to their health.

(Source: Health Sciences Authority)

HIGH EXPOSURE OVER A LONG PERIOD MAY INCREASE CANCER RISK

The recalled products were found to contain trace amounts of a nitrosamine impurity, N-nitro-N-methyl-4-aminobutyric acid (NMBA), which are above internationally accepted levels, HSA said.

Exposure to nitrosamines at high quantities over a long-term period may potentially increase the risk of cancer.

For example, the added cancer risk from an additional six-month exposure is estimated to be less than 0.0002 per cent.

“The risks of trace amounts of NMBA are associated with long term exposure. Sudden stopping of the medicines can pose greater and more immediate risk to patient’s health … We have advised healthcare professionals to review the medicine and treatment plans of their patients,” HSA said.

The affected products contain the active ingredient losartan potassium. (Photo: Health Sciences Authority)

​​​​​​​

Affected consumers are advised to consult their medical providers. (Photo: Health Sciences Authority)

HSA said that several losartan medicines have been recalled overseas since end-February due to the presence of NMBA. It tested all locally marketed losartan products for the presence of the NMBA impurity and in March found the three brands contained trace amounts of NMBA above acceptable levels.

The other seven brands of losartan medicines marketed in Singapore are not affected by this impurity.

image: https://www.channelnewsasia.com/image/11389242/0x0/978/651/a775c2a9b2580e8317c1c066db244f12/SK/losartan-table-2.jpg

(Source: Health Sciences Authority)

NO IMMEDIATE HEALTH RISK

National Heart Centre Singapore Cardiologist Professor Ding Zee Pin said that there is no immediate health risk associated with taking the affected medicines and that patients are advised not to stop or change treatment on their own.

“As losartan is used to treat high blood pressure, stopping the medicine without replacement of other equivalent medication can increase the risk of poor control of blood pressure,” said Professor Ding, who is also on HSA's Expert Panel on Nitrosamines.

Consumers who are taking the affected medication are advised to discuss their treatment plan with their healthcare provider.

“Do not stop taking the medicines on your own until you have been provided with a replacement brand of losartan or a different medicine by your healthcare provider,” HSA said.

MOH said in its release that public healthcare institutions will be reaching out to their patients.

Those with medical appointments scheduled before Jul 1 should proceed with their appointments, at which point their doctor will advise them on alternative medicines, MOH said.

Patients whose medical appointments are scheduled on or after Jul 1 will be contacted for an earlier consultation.

TESTS CONDUCTED ON OTHER BLOOD PRESSURE MEDICATION

Losartan belongs to a class of medicines called angiotensin II receptor blockers (ARBs), which are used to treat high blood pressure, also known as hypertension.

HSA said that since June 2018, several ARB medicines have been recalled overseas due to the presence of two other nitrosamine impurities, N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA).

HSA said it has tested the locally marketed ARB medicines and found that none of them contained unacceptable levels of the two impurities.

"HSA is working with companies and international regulatory agencies to verify the cause of contamination, and to formulate measures to address the issue," it said.

"HSA will require companies to make the necessary changes to their manufacturing process to ensure that the medicines do not contain these impurities in future," it added.

Read more at https://www.channelnewsasia.com/news/singapore/hsa-recalls-3-brands-blood-pressure-drugs-losartan-impurity-11389238